Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia

作者：Lee Sang Hak; Cho Kyoung Im; Kim Jang Young; Ahn Young Keun; Rha Seung Woon; Kim Yong Jin; Choi Yun Seok; Choi Si Wan; Jeon Dong Woon; Min Pil Ki; Choi Dong Ju; Baek Sang Hong; Kim Kwon Sam; Byun Young Sup; Jang Yangsoo^*

来源：Atherosclerosis, 2012, 221(1): 169-175.

DOI：10.1016/j.atherosclerosis.2011.12.042

• Asia
• Creatine kinase
• Fenofibrate
• Rosuvastatin
• Safety

Objective: The aim of this study is to compare the non-lipid effects of rosuvastatin-fenofibrate combination therapy with rosuvastatin monotherapy in high-risk Asian patients with mixed hyperlipidemia. %26lt;br%26gt;Methods: A total of 236 patients were initially screened. After six weeks of diet and life style changes, 180 of these patients were randomly assigned to receive one of two regimens: rosuvastatin 10 mg plus fenofibrate 160 mg or rosuvastatin 10 mg. The primary outcome variables were the incidences of muscle or liver enzyme elevation. The patients were followed for 24 weeks during drug treatment and for an additional four weeks after drug discontinuation. %26lt;br%26gt;Results: The rates of the primary outcome variables were similar between the two groups (2.8% and 3.9% in the combination and the rosuvastatin groups, respectively, p = 1.00). The combination group had more, but not significantly, common treatment-related adverse events (AEs) (13.3% and 5.6%, respectively) and drug discontinuation due to AEs (10.0% and 3.3%, respectively) than the rosouvastatin group. Combination therapy was associated with higher elevations in homocysteine, blood urea nitrogen, and serum creatinine, whereas elevation in alanine aminotransferase was greater in the rosuvastatin group. Leukocyte count and hemoglobin level decreased to a greater extent in the combination group. The combination group showed greater reductions in TG and elevation in HDL-cholesterol. %26lt;br%26gt;Conclusion: In our study population, the rosuvastatin-fenofibrate combination resulted in comparable incidences of myo- or hepatotoxicity as rosuvastatin monotherapy. However, this combination may need to be used with caution in individuals with underlying pathologies such as renal dysNCT01414803).

• 出版日期2012-3